Sugi Predict

Sugi Predict / Compounds / SCHEMBL7957052

SCHEMBL7957052

SCHEMBL7957052

Cc1cccc2c1CN(C)CC2

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAOA P21397 2/20 0.59
▸ MAOB P27338 2/20 0.59
▸ ADRA2A P08913 4/20 0.55
▸ ADRA2B P18089 4/20 0.55
▸ ADRA2C P18825 4/20 0.55
▸ ADRA1D P25100 3/20 0.55
▸ ADRA1A P35348 3/20 0.55
▸ ADRA1B P35368 3/20 0.55
▸ CYP2D6 P10635 1/20 0.55
▸ DRD2 P14416 4/20 0.53
▸ DRD5 P21918 4/20 0.53
▸ DRD3 P35462 4/20 0.53
▸ DRD1 P21728 3/20 0.53
▸ DRD4 P21917 2/20 0.53
▸ NPSR1 Q6W5P4 1/20 0.53
▸ HTR1D P28221 3/20 0.47
▸ HTR1B P28222 3/20 0.47
▸ HTR2A P28223 3/20 0.47
▸ HTR7 P34969 3/20 0.47
▸ HTR2B P41595 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24425269 0.89 MAOA (0.46) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL29507212 0.85 MAOA (0.59) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL12363802 0.85 MAOA (0.59) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL8136380 0.82 ALDH1A1 (0.45) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL11947233 0.79 ALDH1A1 (0.41) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL3186398 0.79 MAOA (0.57) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL19957848 0.79 ALDH1A1 (0.44) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL21195968 0.79 DRD2 (0.75) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL12969652 0.79 ADRA2A (0.79) MAOAMAOBADRA2AADRA2BADRA2C
SCHEMBL24582728 0.79 MAOA (0.57) MAOAMAOBADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 — — US disclosed
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 C4 THERAPEUTICS, INC. (US) 2023-10-26 — — US disclosed
US-20230203007-A1 PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS X-CHEM GLOBAL HQ 2023-06-29 — — US disclosed
WO-2023116763-A1 PYRIDAZINE COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF 上海优理惠生医药有限公司 2023-06-29 — — WO disclosed
WO-2023098832-A1 PYRIDOPYRIMIDINE DERIVATIVES SERVING AS SMALL GTP ENZYME KRAS MUTATION INHIBITORS 思路迪生物医药(上海)有限公司 2023-06-08 — — WO disclosed
EP-3498701-B1 PRMT5 INHIBITORS AND USES THEREOF EPIZYME INC (US) 2023-02-22 — — EP disclosed
US-20230050653-A1 ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) 2023-02-16 — — US disclosed
EP-4104865-A1 ANTI-EGFR ANTIBODY DRUG CONJUGATES AbbVie Inc. (US) 2022-12-21 — — EP disclosed
CN-115073474-A Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof 百济神州有限公司 2022-09-20 — — CN disclosed
CN-115028639-A Pyrrolo [2,3-b ] pyrazines as HPK1 inhibitors and uses thereof 百济神州有限公司 2022-09-09 — — CN disclosed
US-20110195954-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-08-11 — — US disclosed
WO-2010123139-A1 ARYLCARBOXAMIDE DERIVATIVE HAVING SULFAMOYL GROUP 持田製薬株式会社 (JP) 2010-10-28 — — WO disclosed
WO-2010115264-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 — — WO disclosed
US-20100261714-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 — — US disclosed
US-20100261714-A1 INHIBITORS OF HIV REPLICATION BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-10-14 — — US disclosed
WO-2010018874-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — WO disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — US disclosed
US-20100041891-A1 AMIDE COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — US disclosed
US-7157463-B2 Substituted piperidines/piperazines as melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-01-02 — — US disclosed
US-7157463-B2 Substituted piperidines/piperazines as melanocortin receptor agonists ELI LILLY AND COMPANY (US) 2007-01-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041891-A1 AMIDE COMPOUND GPR52, GPR132, NR5A2 MAOA 468/4885MAOB 1106/4885ADRA2A 14/4885
US-20230339902-A1 TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 IKZF1, IKZF3, IKZF2 MAOA 4265/4885MAOB 4489/4885ADRA2A 4699/4885
US-20230203007-A1 PYRIDINYLACETAMIDE DERIVATIVES AS SODIUM CHANNEL ACTIVATORS SCN1A, SCN3A, SCN2A MAOA 385/4885MAOB 1146/4885ADRA2A 280/4885
US-20110195954-A1 NOVEL COMPOUNDS CALCRL, CALCR, CALCA MAOA 700/4885MAOB 702/4885ADRA2A 155/4885
US-20230050653-A1 ROCK INHIBITOR AND PREPARATION METHOD THEREFOR AND USE THEREOF ROCK1, CYP11B1, CYP4A11 MAOA 993/4885MAOB 743/4885ADRA2A 3336/4885
US-20100261714-A1 INHIBITORS OF HIV REPLICATION RTF2, POLR1A, REV1 MAOA 1033/4885MAOB 989/4885ADRA2A 1350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.